2Pitt B, Zannad F, Remme WJ, et al. For the randomized Aldactone Evaluation Study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med, 1999,341:709 - 711
3Delyani JA. Anti-aldosterone therapy in the treatment of heart failure new thoughts on an old hormone. Exp Qpin Invest Drugs, 1998,7:753- 759
4Duprez DA, Bauwens FR, De Buyzere ML, et al.Influence of blood pressure and aldosterone on left ventriculasr hypertrophy in moderate essential hypertention. Am J Cardiol, 1993,71:17A - 20A
5Swedberg K, Eneroth P, Kjekshus J, et al. For the CONSENUS Trail Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation,1999,82:1730 - 1736
6Brilla CG, Matsubara LS, Weber KT. Antifibrotic effect of spironalactone in preventing myocardial fibrosis in systemic arterial hypertention. Am J Cardiol, 1993,71:12A - 16A
7Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium:fibrosis and renin-angiotensin-aldosterone system. Circulation, 1991,83:1849- 1865
8Brunner HR, Laragg JH, Newton MA, et al. Essential hypertention: rennin and aldosterone, heart attack and stroke. N Engl J Med, 1972,286:441 -449
7Tonkon M, Awan N, NiaziI, et al. Astudy of the efficacy and safetyofirbe zsartanineombination with eonventio naltherapy, including ACE Iinhibitorsinhearthailure[ J ]. Int J Clin Prat, 2000,24 ( 1 ) :11.
8Tonkon M, Awan N, Niazi I, et al. A study of the efficacy and safe 2tyofirbezsartanin combination with conventional therapy, includingACE Iinhibitorsinheart failure. Int J Clin Prat ,2000,24 ( 1 ) : 11.
